To cite this paper use one of the standards below:
INTRODUCTION: Disease-modifying therapies (DMTs) effectively reduce multiple sclerosis (MS) relapses and improve survival, yet data on their efficacy and safety in older patients are limited. DISCOMS, the first trial of DMT discontinuation in MS, focused on patients aged over 55 years with stable disease, failed to demonstrate non-inferiority in discontinuation versus continuation for relapse or new lesions. OBJECTIVES: To provide additional real-world evidence on discontinuing MS medication, particularly among older patients with stable disease, mirroring the inclusion criteria of the DISCOMS trial. METHODS: We conducted a retrospective observational study, reviewing records of MS patients aged 55 or older with no relapses in 5 years and no new MRI lesions in 3 years on DMT, consecutively seen between August 2023 and October 2023. Primary endpoints were time to first disease activity, defined as a new MS relapse or MRI lesion. Suitable statistical tests compared groups, and Kaplan-Meier curves depicted time-to-event outcomes, utilizing R, version 4.2.0. RESULTS: Of 436 assessed patients, 46 were included, with 18 (39.1%) discontinuing treatment. The majority of patients (N = 20; 47%) were treated with injectable therapies. Over a fifth of patients were treated with unapproved therapies, reflecting treatment exposure prior to DMT availability (N = 9; 21.3%). A significant difference in baseline radiological stability duration favored discontinuation (median: 7.1 vs 5.1 years; p = 0.042), potentially impacting the decision to halt treatment. Following discontinuation, 8 patients (53%) experienced disease activity, yet no notable discrepancy in outcomes was observed between the assessed groups. Additionally, there was no significant variance in the time to disease activity (aHR=1.07, 95% CI 0.84 to 1.37; p=0.584). CONCLUSION: Despite age-related expectations, our study found higher disease activity compared to DISCOMS. Yet, no significant differences between discontinuers and continuers were detected, suggesting that age might be the predominant factor influencing DMT cessation.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper